Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GLYCAR T cells |
Synonyms | |
Therapy Description |
GLYCAR T cells consist of a preparation of autologous peripheral blood mononuclear cells engineered to express a chimeric antigen receptor (CAR) targeting GPC3 linked to CD8 alpha hinge domain, CD28 transmembrane domain, and CD3zeta signaling domain, which may lead to antitumor activity, including reduced tumor growth in GPC3-positive tumor cells (PMID: 32371538). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GLYCAR T cells | GPC3 CAR T cells|CAR-GPC3 T Cells|Glypican-3 CAR T Cells | GLYCAR T cells consist of a preparation of autologous peripheral blood mononuclear cells engineered to express a chimeric antigen receptor (CAR) targeting GPC3 linked to CD8 alpha hinge domain, CD28 transmembrane domain, and CD3zeta signaling domain, which may lead to antitumor activity, including reduced tumor growth in GPC3-positive tumor cells (PMID: 32371538). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02905188 | Phase I | GLYCAR T cells Cyclophosphamide + Fludarabine | Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) | Completed | USA | 0 |